Clinical Trial Update: A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia [Phase 2]

View source ↗

Summary

Phase 2 proof-of-mechanism study of multiple oral doses of Fevipiprant (QAW039) in COPD patients with eosinophilia; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Fevipiprant (fevipiprant)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: TERMINATED | Results posted: 2021-01-25